Your session is about to expire
← Back to Search
Radiation Therapy
Advanced imaging for radiotherapy planning and guidance for Prostate Cancer
N/A
Waitlist Available
Led By Peter Chung, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Low or intermediate risk localized prostate cancer: Gleason score ≤ 7, PSA <20, Stage T2a or less, <50% of biopsy cores involved with tumor
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights
Study Summary
This trial will study whether reducing the amount of radiation delivered to normal tissues during prostate cancer treatment improves patient outcomes.
Who is the study for?
This trial is for men with low or intermediate risk localized prostate cancer, specifically those with a Gleason score of 7 or less, PSA under 20, and no more than half of biopsy cores involved with tumor. It's not for men who've had hip replacements, inflammatory bowel diseases, severe reactions to prostate biopsies, or are on certain anticoagulant therapies.Check my eligibility
What is being tested?
The study tests if using advanced MRI in planning and daily CBCT imaging during treatment can improve outcomes by reducing radiation doses to non-cancerous parts like the rectum and bladder. The trial has two stages: first integrating advanced imaging without changing dose plans; secondly reducing doses to healthy tissues.See study design
What are the potential side effects?
While the trial focuses on minimizing side effects by precisely targeting radiation, potential risks may include typical radiotherapy side effects such as skin irritation at the treatment site, fatigue, urinary issues, and gastrointestinal discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My prostate cancer is at an early stage, with a low Gleason score, PSA under 20, and limited tumor involvement.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To determine whether reducing the dose to normal tissues, enabled by the integration of advanced imaging, reduces the incidence of RTOG/CTC Grade ≥ 2 toxicity.
Secondary outcome measures
To determine whether reducing the dose to normal tissues, enabled by the integration of advanced imaging, improves quality of life in patients receiving external beam radiotherapy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: MRI + CBCT in prostate cancerExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Princess Margaret Hospital, CanadaOTHER
118 Previous Clinical Trials
38,595 Total Patients Enrolled
9 Trials studying Prostate Cancer
9,540 Patients Enrolled for Prostate Cancer
University Health Network, TorontoLead Sponsor
1,456 Previous Clinical Trials
482,774 Total Patients Enrolled
64 Trials studying Prostate Cancer
15,440 Patients Enrolled for Prostate Cancer
Peter Chung, MDPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
267 Total Patients Enrolled
2 Trials studying Prostate Cancer
57 Patients Enrolled for Prostate Cancer
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the data collection phase of this experiment accepting volunteers?
"This medical trial, which was initially announced on September 1st 2006 and last edited on October 21st 2022 is no longer accepting enrollees. However, 1253 other clinical trials are currently recruiting patients."
Answered by AI
Share this study with friends
Copy Link
Messenger